がんモノクローナル抗体市場：タイプ、用途、エンドユーザー別-2025-2030年の世界予測

がんモノクローナル抗体市場は、2023年に698億7,000万米ドルと評価され、2024年には786億米ドルに達すると予測され、CAGR 12.89％で成長し、2030年には1,632億8,000万米ドルに達すると予測されています。

がんモノクローナル抗体（mAbs）は、がん治療において極めて重要な進歩であり、健康な組織を温存しながらがん細胞を特異的に攻撃する標的治療アプローチが特徴です。その必要性は、がんの蔓延が拡大していることと、化学療法や放射線療法といった従来の治療法に比べて、より効果的で毒性の低い治療法が求められていることから生じています。mAbsの応用は多くのがん種に及び、乳がん、大腸がん、非ホジキンリンパ腫、肺がんなどに大きな有用性があります。最終用途は主に病院、専門クリニック、精密医療に携わる研究機関です。市場の洞察によれば、抗体工学の技術的進歩、官民の研究開発投資の増加、新治療法の規制当局による承認の増加が、市場の堅調な成長を牽引しています。個別化医療におけるmAbの統合、患者層別化のためのコンパニオン診断の活用、複数の抗原を同時に標的とする二特異性モノクローナル抗体の活用など、機会は豊富にあります。主な課題としては、高い開発コスト、複雑な製造プロセス、厳しい規制要件などがあり、これらは中小企業の市場参入を妨げる可能性があります。市場の成長は、バイオシミラー競争による独占的価格設定の可能性の低下と並んで、新興地域における限られた認知度とアクセスによっても阻害されています。抗体薬物複合体の改良、人工知能を活用した創薬、免疫チェックポイント阻害剤併用療法の研究などが、事業成長のための革新的技術です。新たなビジネスチャンスを生かすために、企業は戦略的提携に注力し、臨床試験を世界に拡大し、治療へのアクセス性を高めるために有利な償還政策を提唱すべきです。市場はダイナミックであり、急速な技術進歩と進化する規制状況を特徴としているため、機敏な戦略と継続的な適応が必要となります。利害関係者は、このような動向に合わせ、開発・運用上のハードルに取り組むことで、拡大するがんモノクローナル抗体の治療的・商業的可能性を効果的に活用することができます。

市場力学：急速に進化するがんモノクローナル抗体市場の主要市場インサイトを公開

がんモノクローナル抗体市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の各種がんの有病率の上昇
  • 免疫反応を改善・抑制するがんモノクローナル抗体に対する意識の高まり
  • 強固なパイプラインに伴う医薬品承認の増加
• 市場抑制要因
  • モノクローナル抗体の回収件数の急増
• 市場機会
  • 新規モノクローナル抗体の臨床試験の増加
  • がんモノクローナル抗体開発のための共同アプローチ
• 市場の課題
  • モノクローナル抗体の製造に伴う規制や技術的な複雑さ

ポーターの5つの力：がんモノクローナル抗体市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：がんモノクローナル抗体市場における外部からの影響の把握

外部マクロ環境要因は、がんモノクローナル抗体市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析がんモノクローナル抗体市場における競合情勢の把握

がんモノクローナル抗体市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスがんモノクローナル抗体市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、がんモノクローナル抗体市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨がんモノクローナル抗体市場における成功への道筋を描く

がんモノクローナル抗体市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中でさまざまながんの罹患率が上昇
    • 免疫反応を改善し抑制するためのがんモノクローナル抗体の認知度向上
    • 強力なパイプラインとともに医薬品の承認数も増加
  • 抑制要因
    • モノクローナル抗体の回収数が急増
  • 機会
    • 新たに開発されたモノクローナル抗体の臨床試験の増加
    • がんモノクローナル抗体の開発に向けた共同アプローチ
  • 課題
    • モノクローナル抗体の製造に関連する規制上および技術的な複雑さ
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 がんモノクローナル抗体市場：タイプ別

• キメラ
• 人間
• 人間化
• ネズミ

第7章 がんモノクローナル抗体市場：用途別

• 血液がん
• 乳がん
• 大腸がん
• 肝臓がん
• 肺がん
• 悪性黒色腫

第8章 がんモノクローナル抗体市場：エンドユーザー別

• 病院
• 調査機関
• 調査室

第9章 南北アメリカのがんモノクローナル抗体市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のがんモノクローナル抗体市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのがんモノクローナル抗体市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Agilent Technologies, Inc.
• Amgen, Inc.
• Astrazeneca PLC
• Bayer AG
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Bristol Myers Squibb Co.
• Celldex Therapeutics, Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Gilead Sciences, Inc.
• GSK PLC
• Incyte Corporation
• Johnson & Johnson
• Merck & Co.
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Qiagen N.V.
• Sanofi S.A.
• Sartorius AG
• Seagen Inc.
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH PROCESS
• FIGURE 2. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. CANCER MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. CANCER MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CANCER MONOCLONAL ANTIBODIES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CANCER MONOCLONAL ANTIBODIES MARKET DYNAMICS
• TABLE 7. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MURINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 33. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 34. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 35. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 37. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. AUSTRALIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. AUSTRALIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. CHINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. CHINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. CHINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. INDIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 54. INDIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. INDIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 57. INDONESIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. INDONESIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 63. MALAYSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. MALAYSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. PHILIPPINES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. PHILIPPINES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 69. SINGAPORE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. SINGAPORE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. SOUTH KOREA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. SOUTH KOREA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 75. TAIWAN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. TAIWAN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. THAILAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. THAILAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 81. VIETNAM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. VIETNAM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 86. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. DENMARK CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. DENMARK CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 91. EGYPT CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. EGYPT CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. FINLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. FINLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 103. ISRAEL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. ISRAEL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. ITALY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 106. ITALY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 107. ITALY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 109. NETHERLANDS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 110. NETHERLANDS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 112. NIGERIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. NIGERIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 115. NORWAY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 116. NORWAY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 117. POLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 118. POLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. POLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. QATAR CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 121. QATAR CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. QATAR CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 124. RUSSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. RUSSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 128. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 134. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SWEDEN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. SWEDEN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 139. SWITZERLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 140. SWITZERLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 142. TURKEY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 143. TURKEY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED ARAB EMIRATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 146. UNITED ARAB EMIRATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 148. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 149. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 150. CANCER MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 151. CANCER MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023

The Cancer Monoclonal Antibodies Market was valued at USD 69.87 billion in 2023, expected to reach USD 78.60 billion in 2024, and is projected to grow at a CAGR of 12.89%, to USD 163.28 billion by 2030.

Cancer monoclonal antibodies (mAbs) represent a pivotal advancement in oncology, marked by their targeted therapeutic approach which specifically attacks cancer cells while sparing healthy tissues. Their necessity arises from the growing prevalence of cancer and the need for more effective, less toxic treatment alternatives compared to traditional options like chemotherapy and radiation. The application of mAbs spans numerous cancer types, with significant utility in breast, colorectal, non-Hodgkin's lymphoma, and lung cancers. End-use scope mainly involves hospitals, specialty clinics, and research institutes engaged in precision medicine. Market insights reveal robust growth driven by technological advancements in antibody engineering, rising public and private R&D investments, and increased regulatory approvals for new therapies. Opportunities abound with the integration of mAbs in personalized medicine, harnessing companion diagnostics for patient stratification, and utilizing bispecific monoclonal antibodies to target multiple antigens simultaneously. Key challenges include high development costs, complex manufacturing processes, and stringent regulatory requirements, which can impede smaller players from entering the market. Market growth is also hindered by limited awareness and access in emerging regions, alongside biosimilar competition decreasing monopoly pricing potential. Innovations poised for business growth lie in improving antibody-drug conjugates, leveraging artificial intelligence for drug discovery, and exploring immune checkpoint inhibitors combination therapies. To capitalize on emerging opportunities, companies should focus on strategic collaborations, expand clinical trials globally, and advocate for favorable reimbursement policies to enhance treatment accessibility. The market is dynamic, characterized by rapid technological progress and evolving regulatory landscapes, necessitating agile strategies and continuous adaptation. By aligning with these trends and tackling developmental and operational hurdles, stakeholders can leverage the expanding therapeutic and commercial potential of cancer monoclonal antibodies effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Monoclonal Antibodies Market

The Cancer Monoclonal Antibodies Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of different cancers worldwide
  • Growing awareness of cancer monoclonal antibodies to improve & suppress the immune responses
  • Increasing drug approvals along with a robust pipeline
• Market Restraints
  • Surging number of withdrawals of monoclonal antibodies
• Market Opportunities
  • Increasing clinical trials of newly developed monoclonal antibodies
  • Collaborative approach for development of cancer monoclonal antibodies
• Market Challenges
  • Regulatory and technical complications associated with manufacture of monoclonal antibodies

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Monoclonal Antibodies Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Monoclonal Antibodies Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Monoclonal Antibodies Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Monoclonal Antibodies Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Monoclonal Antibodies Market

A detailed market share analysis in the Cancer Monoclonal Antibodies Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Monoclonal Antibodies Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Monoclonal Antibodies Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Monoclonal Antibodies Market

A strategic analysis of the Cancer Monoclonal Antibodies Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Monoclonal Antibodies Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Agilent Technologies, Inc., Amgen, Inc., Astrazeneca PLC, Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bristol Myers Squibb Co., Celldex Therapeutics, Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GSK PLC, Incyte Corporation, Johnson & Johnson, Merck & Co., Merck KGaA, Novartis AG, Pfizer Inc., Qiagen N.V., Sanofi S.A., Sartorius AG, Seagen Inc., Takara Bio Inc., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Cancer Monoclonal Antibodies Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Chimeric, Human, Humanized, and Murine.
• Based on Application, market is studied across Blood Cancer, Breast Cancer, Colorectal Cancer, Liver Cancer, Lung Cancer, and Melanoma.
• Based on End-user, market is studied across Hospitals, Research Institutes, and Research Laboratories.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of different cancers worldwide
    • 5.1.1.2. Growing awareness of cancer monoclonal antibodies to improve & suppress the immune responses
    • 5.1.1.3. Increasing drug approvals along with a robust pipeline
  • 5.1.2. Restraints
    • 5.1.2.1. Surging number of withdrawals of monoclonal antibodies
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing clinical trials of newly developed monoclonal antibodies
    • 5.1.3.2. Collaborative approach for development of cancer monoclonal antibodies
  • 5.1.4. Challenges
    • 5.1.4.1. Regulatory and technical complications associated with manufacture of monoclonal antibodies
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cancer Monoclonal Antibodies Market, by Type

• 6.1. Introduction
• 6.2. Chimeric
• 6.3. Human
• 6.4. Humanized
• 6.5. Murine

7. Cancer Monoclonal Antibodies Market, by Application

• 7.1. Introduction
• 7.2. Blood Cancer
• 7.3. Breast Cancer
• 7.4. Colorectal Cancer
• 7.5. Liver Cancer
• 7.6. Lung Cancer
• 7.7. Melanoma

8. Cancer Monoclonal Antibodies Market, by End-user

• 8.1. Introduction
• 8.2. Hospitals
• 8.3. Research Institutes
• 8.4. Research Laboratories

9. Americas Cancer Monoclonal Antibodies Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Cancer Monoclonal Antibodies Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Cancer Monoclonal Antibodies Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Agilent Technologies, Inc.
• 3. Amgen, Inc.
• 4. Astrazeneca PLC
• 5. Bayer AG
• 6. Becton, Dickinson and Company
• 7. Bio-Rad Laboratories, Inc.
• 8. Bristol Myers Squibb Co.
• 9. Celldex Therapeutics, Inc.
• 10. Eli Lilly and Company
• 11. F. Hoffmann-La Roche AG
• 12. Gilead Sciences, Inc.
• 13. GSK PLC
• 14. Incyte Corporation
• 15. Johnson & Johnson
• 16. Merck & Co.
• 17. Merck KGaA
• 18. Novartis AG
• 19. Pfizer Inc.
• 20. Qiagen N.V.
• 21. Sanofi S.A.
• 22. Sartorius AG
• 23. Seagen Inc.
• 24. Takara Bio Inc.
• 25. Thermo Fisher Scientific Inc.